Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1215-1221

  Felice, María S ^a   Gallego, Marta S ^b   Alonso, Cristina N ^a   Alfaro, Elizabeth M ^a   Guitter, Myriam R ^a   Bernasconi, Andrea R ^a   Rubio, Patricia L ^a   Zubizarreta, Pedro A ^a   Rossi, Jorge G ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^b Cytogenetics ^*  (Argentina)

Author keywords

Acute lymphoblastic leukemia; childhood; E2A PBX1 fusion transcript; prognostic value; t(1; 19)

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; METHOTREXATE; PREDNISONE; TIOGUANINE; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTION FACTOR PBX1; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CYTOGENETICS; EVENT FREE SURVIVAL; HUMAN; IMMUNOPHENOTYPING; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CHILD; CHILD, PRESCHOOL; CYTOGENETIC ANALYSIS; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; HUMANS; IMMUNOPHENOTYPING; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; VINCRISTINE;

EID: 79959600263     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.565436     Document Type: Article

References (20)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-1548.
2. Carroll W, Bhojwani D, Min D, et al. Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2003:102-131.
3. Pui CH, Raimondi SC, Hancock ML, et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19)(q23;p13) or its derivative. J Clin Oncol 1994;12:2601-2606.
4. Crist WM, Carroll AJ, Slmster JJ, et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group Study. Blood 1990;76:117-122. (Pubitemid 20220799)
5. Secker-Walker LM, Berger R, Fenaux P, et al. Prognostic significance of the balanced t(1;19) and unbalanced der(19)t(1;19) translocations in acute lymphoblastic leukemia. Leukemia 1992;6:363-369.
6. Uckun F, Sensel M, Sather H, et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 1998;16: 527-535. (Pubitemid 28135595)
7. Burmeister T, Gökbuget N, Schwartz S, et al. Clinical features and prognostic implications of TCF3-PBX1 and ETV6- RUNX1 in adult acute lymphoblastic leukemia. Haematologica 2010;95:241-246.
8. Borowitz MJ, Chan JKC. Precursor lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008. pp 167-178.
9. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-1786.
10. Shaffer LG, Slovak ML, Campbell LJ. ISCN (2009): an international system for human cytogenetic nomenclature. Basel: S. Karger; 2009.
11. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-1928.
12. Sackmann-Muriel F, Felice M, Zubizarreta P, et al. Treatment results in childhood acute lymphoblastic leukemia with a modified ALL-BFM'90 protocol: lack of improvement in high-risk group. Leuk Res 1999;23: 331-340. (Pubitemid 29166766)
13. Felice MS, Rossi J, Gallego MS, et al. Evolución en el tratamiento de la leucemia linfoblástica aguda en el Hospital de Pediatría Prof. Dr. Juan P. Garrahan. Med Infant 2007;14: 92-100.
14. Pieters R, Schrappe M, De Lorenzo P, et al. Outcome of infants less than one year of age with acute lymphoblastic leukemia treated with the Interfant-99 protocol. Lancet 2007;370:240-250. (Pubitemid 47082422)
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1995;53:457-481.
16. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation on each patient. II Analysis and examples. Br J Cancer 1997;35:1-39.
17. Tarone RE, Wara J. On distribution-free tests for equality of survival distributions. Biometrika 1997;64:156-160.
18. Raimondi SC, Behm FG, Roberson PK, et al. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol 1990;8: 1380-1388. (Pubitemid 20252310)
19. Pui CH, Campana D, Pei D, et al. Treatment of childhood acute lymphoblastic leukemia without prophylactic cranial irradiation. N Engl J Med 2009;360:2730-2741.
20. Jeha S, Pei D, Raimondi S, et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009;23:1406-1409.